Dronabinol is under clinical development by IGC Pharma and currently in Phase II for Dementia Associated With Alzheimer’s Disease. According to GlobalData, Phase II drugs for Dementia Associated With Alzheimer’s Disease have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dronabinol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dronabinol overview

IGC-AD1 (tetrahydrocannabinol) is under development for the treatment of mild to moderate dementia due to Alzheimer's disease. The drug candidate is a cannabinoid that acts by targeting glycogen synthase kinase-3 beta (GSK3b). It is administered through oral or sublingual route.

IGC Pharma overview

IGC Pharma focuses on cannabinoid research and the development of hemp-based pharmaceuticals and wellness solutions. IGC Pharma is headquartered in Potomac, Maryland, the US.

For a complete picture of Dronabinol’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.